Was listening to Piramal Pharma’s Q4 concall.
Broad brush takeaways –
Piramal Pharma can potentially clock 1200 cr plus EBITDA for FY 24
Profitability at PAT levels also likely to improve significantly next year
Most improvements to accelerate in H2 FY 24
Beauty is the the eye of beholder
Everyone can judge for themselves wrt current Mkt Cap
Disc: biased, holding a tracking position
| Subscribe To Our Free Newsletter |
